Free Trial

HCA Healthcare (HCA) Financials

HCA Healthcare logo
$428.01 -1.68 (-0.39%)
Closing price 05/13/2026 03:59 PM Eastern
Extended Trading
$427.28 -0.72 (-0.17%)
As of 06:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for HCA Healthcare

Annual Income Statements for HCA Healthcare

This table shows HCA Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
2,129 2,890 2,216 3,787 3,505 3,754 6,956 5,643 5,242 5,760 6,784
Consolidated Net Income / (Loss)
2,696 3,432 2,743 4,389 4,145 4,387 7,721 6,834 6,091 6,657 7,782
Net Income / (Loss) Continuing Operations
2,696 3,432 2,743 4,389 4,145 4,387 7,721 6,834 6,091 6,657 7,782
Total Pre-Tax Income
3,957 4,810 4,381 5,335 5,244 5,430 9,833 8,580 7,706 8,523 9,832
Total Operating Income
5,960 6,467 6,065 7,090 7,236 7,255 11,298 10,354 9,622 10,584 12,080
Total Gross Profit
21,563 22,593 36,298 17,528 42,855 27,659 31,973 50,862 35,481 28,678 31,374
Total Revenue
43,591 41,490 43,614 46,677 51,336 51,533 58,752 60,233 64,968 70,603 75,600
Operating Revenue
43,591 41,490 43,614 46,677 51,336 51,533 58,752 60,233 64,968 70,603 75,600
Total Cost of Revenue
22,028 18,897 7,316 29,149 8,481 23,874 26,779 9,371 29,487 41,925 44,226
Operating Cost of Revenue
18,115 18,897 7,316 29,149 8,481 23,874 26,779 9,371 29,487 41,925 44,226
Total Operating Expenses
15,603 16,126 30,233 10,438 35,619 20,404 20,675 40,508 25,859 18,094 19,294
Selling, General & Admin Expense
13,694 14,429 28,110 8,608 33,041 17,676 19,442 38,840 22,777 14,819 15,886
Depreciation Expense
1,904 1,966 2,131 2,278 2,596 2,721 2,853 2,969 3,077 3,312 3,523
Other Operating Expenses / (Income)
- -246 - -20 - - - - - -23 -78
Other Special Charges / (Income)
5.00 -23 -8.00 -428 -18 7.00 -1,620 -1,301 5.00 -14 -37
Total Other Income / (Expense), net
-2,003 -1,657 -1,684 -1,755 -1,992 -1,825 -1,465 -1,774 -1,916 -2,061 -2,248
Interest Expense
1,800 1,711 1,729 1,755 2,035 1,879 1,578 1,819 1,938 2,061 2,248
Income Tax Expense
1,261 1,378 1,638 946 1,099 1,043 2,112 1,746 1,615 1,866 2,050
Net Income / (Loss) Attributable to Noncontrolling Interest
567 542 527 602 640 633 765 1,191 849 897 998
Basic Earnings per Share
$5.14 $7.53 $6.12 $10.90 $10.27 $11.10 $21.52 $19.43 $19.25 $22.27 $28.70
Weighted Average Basic Shares Outstanding
414.19M 383.59M 362.31M 347.30M 341.21M 338.27M 323.32M 290.35M 272.40M 258.60M 236.41M
Diluted Earnings per Share
$4.99 $7.30 $5.95 $10.66 $10.07 $10.93 $21.16 $19.15 $18.97 $22.00 $28.33
Weighted Average Diluted Shares Outstanding
426.72M 395.85M 372.22M 355.30M 348.23M 343.61M 328.75M 294.67M 276.41M 261.81M 239.50M
Weighted Average Basic & Diluted Shares Outstanding
414.20M 383.80M 362.10M 347.40M 338.43M 339.92M 303.60M 276.97M 264.50M 248.34M 223.62M
Cash Dividends to Common per Share
- - - $1.40 $1.60 $0.43 $1.92 $2.24 $2.40 $2.64 $2.88

Quarterly Income Statements for HCA Healthcare

This table shows HCA Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
1,079 1,607 1,591 1,461 1,270 1,438 1,610 1,653 1,643 1,878 1,620
Consolidated Net Income / (Loss)
1,275 1,861 1,802 1,687 1,482 1,686 1,825 1,891 1,903 2,163 1,857
Net Income / (Loss) Continuing Operations
1,275 1,861 1,802 1,687 1,482 1,686 1,825 1,891 1,903 2,163 1,857
Total Pre-Tax Income
1,630 2,345 2,247 2,237 1,906 2,133 2,327 2,415 2,418 2,672 2,287
Total Operating Income
2,094 2,826 2,759 2,743 2,406 2,676 2,856 2,964 2,963 3,297 2,862
Total Gross Profit
8,657 4,934 6,961 14,858 9,626 -2,767 10,324 10,467 10,797 -214 10,826
Total Revenue
16,213 17,303 17,339 17,492 17,487 18,285 18,321 18,605 19,161 19,513 19,109
Operating Revenue
16,213 17,303 17,339 17,492 17,487 18,285 18,321 18,605 19,161 19,513 19,109
Total Cost of Revenue
7,556 12,369 10,378 2,634 7,861 21,052 7,997 8,138 8,364 19,727 8,283
Operating Cost of Revenue
7,556 12,369 10,378 2,634 7,861 21,052 7,997 8,138 8,364 19,727 8,283
Total Operating Expenses
6,563 2,108 4,202 12,115 7,220 -5,443 7,468 7,503 7,834 -3,511 7,964
Selling, General & Admin Expense
5,796 1,344 3,606 11,308 6,374 -6,469 6,609 6,637 6,943 -4,303 7,033
Depreciation Expense
769 789 795 819 842 856 860 863 889 911 930
Other Special Charges / (Income)
-2.00 -7.00 -201 -12 4.00 195 -1.00 3.00 2.00 -41 1.00
Total Other Income / (Expense), net
-464 -481 -512 -506 -500 -543 -529 -549 -545 -625 -575
Interest Expense
483 491 512 506 515 528 547 568 561 572 584
Interest & Investment Income
19 - - 0.00 15 - 18 19 16 - 9.00
Income Tax Expense
355 484 445 550 424 447 502 524 515 509 430
Net Income / (Loss) Attributable to Noncontrolling Interest
196 254 211 226 212 248 215 238 260 285 237
Basic Earnings per Share
$3.98 $6.00 $6.01 $5.60 $4.94 $5.72 $6.52 $6.91 $7.05 $8.22 $7.25
Weighted Average Basic Shares Outstanding
271.17M 272.40M 264.44M 261.16M 256.76M 258.60M 246.94M 239.17M 232.89M 236.41M 223.59M
Diluted Earnings per Share
$3.91 $5.92 $5.93 $5.53 $4.88 $5.66 $6.45 $6.83 $6.96 $8.09 $7.15
Weighted Average Diluted Shares Outstanding
275.42M 276.41M 268.02M 264.07M 259.92M 261.81M 249.44M 241.91M 236.18M 239.50M 226.65M
Weighted Average Basic & Diluted Shares Outstanding
267.66M 264.50M 261.91M 258.07M 253.30M 248.34M 240.57M 233.99M 228.19M 223.62M 221.84M
Cash Dividends to Common per Share
$0.60 - $0.66 $0.66 - - $0.72 $0.72 - - $0.78

Annual Cash Flow Statements for HCA Healthcare

This table details how cash moves in and out of HCA Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
175 -95 86 -215 119 1,172 -342 -543 27 998 -893
Net Cash From Operating Activities
4,633 5,653 5,426 6,761 7,602 9,232 8,959 8,522 9,431 10,514 12,636
Net Cash From Continuing Operating Activities
4,734 5,653 5,426 6,761 7,602 9,232 8,959 8,522 9,431 10,514 12,636
Net Income / (Loss) Continuing Operations
2,696 3,432 2,743 4,389 4,145 4,387 7,721 6,834 6,091 6,657 7,782
Consolidated Net Income / (Loss)
2,696 3,432 2,743 4,389 4,145 4,387 7,721 6,834 6,091 6,657 7,782
Depreciation Expense
1,904 1,966 2,131 2,278 2,596 2,721 2,853 2,969 3,077 3,312 3,523
Amortization Expense
35 34 31 31 30 30 27 29 35 35 44
Non-Cash Adjustments To Reconcile Net Income
4,595 56 315 -44 669 775 -1,069 -729 456 594 559
Changes in Operating Assets and Liabilities, net
-4,597 165 206 107 162 1,319 -573 -581 -228 -84 728
Net Cash From Investing Activities
-2,583 -3,240 -4,279 -3,901 -5,720 -3,393 -2,643 -3,389 -5,317 -4,933 -4,988
Net Cash From Continuing Investing Activities
-2,583 -3,240 -4,279 -3,901 -5,720 -3,393 -2,643 -3,389 -5,317 -4,933 -4,988
Purchase of Property, Plant & Equipment
-2,375 -2,760 -3,015 -3,573 -4,158 -2,835 -3,577 -4,395 -4,744 -4,875 -4,944
Purchase of Investments
-351 -576 -1,285 -1,253 -1,682 -568 -1,105 -224 -635 -266 -397
Divestitures
73 26 25 808 61 68 2,160 1,237 193 328 269
Sale and/or Maturity of Investments
63 64 - 57 25 -20 -117 14 -112 -115 72
Other Investing Activities, net
7.00 6.00 -4.00 60 34 -38 -4.00 -21 -19 -5.00 12
Net Cash From Financing Activities
-1,976 -2,508 -1,061 -3,075 -1,771 -4,677 -6,655 -5,656 -4,094 -4,582 -8,550
Net Cash From Continuing Financing Activities
-1,976 -2,508 -1,061 -3,075 -1,771 -4,677 -6,655 -5,656 -4,094 -4,582 -8,550
Repayment of Debt
-4,632 -4,723 -824 -2,617 -6,099 -6,157 -1,411 -2,975 -2,206 -4,634 -5,451
Repurchase of Common Equity
-2,397 -2,751 -2,051 -1,530 -1,031 -441 -8,215 -7,000 -3,811 -6,042 -10,067
Payment of Dividends
-495 -434 -448 -928 -1,092 -779 -1,373 -1,678 -1,301 -1,401 -1,506
Issuance of Debt
5,548 5,400 2,262 2,000 6,451 2,700 4,344 5,997 3,224 7,495 8,474
Effect of Exchange Rate Changes
- - - - 8.00 10 -3.00 -20 - - 9.00
Cash Interest Paid
1,650 1,666 1,700 1,744 1,914 1,607 1,502 1,662 1,892 1,938 2,207
Cash Income Taxes Paid
1,186 1,255 1,205 872 849 1,002 2,182 1,175 1,386 1,844 1,740

Quarterly Cash Flow Statements for HCA Healthcare

This table details how cash moves in and out of HCA Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
29 44 349 -453 2,057 -955 -873 -121 58 43 -100
Net Cash From Operating Activities
2,479 2,674 2,469 1,971 3,515 2,559 1,651 4,210 4,416 2,359 2,014
Net Cash From Continuing Operating Activities
2,479 2,674 2,469 1,971 3,515 2,559 1,651 4,210 4,416 2,359 2,014
Net Income / (Loss) Continuing Operations
1,275 1,861 1,802 1,687 1,482 1,686 1,825 1,891 1,903 2,163 1,857
Consolidated Net Income / (Loss)
1,275 1,861 1,802 1,687 1,482 1,686 1,825 1,891 1,903 2,163 1,857
Depreciation Expense
769 789 795 819 842 856 860 863 889 911 930
Amortization Expense
9.00 9.00 9.00 8.00 9.00 9.00 11 14 7.00 12 11
Non-Cash Adjustments To Reconcile Net Income
99 73 -51 187 117 341 150 150 151 108 154
Changes in Operating Assets and Liabilities, net
327 -58 -86 -730 1,065 -333 -1,195 1,292 1,466 -835 -938
Net Cash From Investing Activities
-1,312 -1,597 -903 -1,332 -1,352 -1,346 -1,032 -1,251 -1,388 -1,317 -1,282
Net Cash From Continuing Investing Activities
-1,312 -1,597 -903 -1,332 -1,352 -1,346 -1,032 -1,251 -1,388 -1,317 -1,282
Purchase of Property, Plant & Equipment
-1,147 -1,159 -1,118 -1,281 -1,191 -1,285 -991 -1,176 -1,288 -1,489 -1,119
Purchase of Investments
-157 -354 -96 -35 -93 -42 -227 -99 -35 -36 -265
Divestitures
11 10 310 1.00 1.00 16 161 6.00 10 92 3.00
Sale and/or Maturity of Investments
-14 -82 2.00 -16 -71 -30 28 13 -67 98 103
Other Investing Activities, net
-5.00 -12 -1.00 -1.00 2.00 -5.00 -3.00 5.00 -8.00 18 -4.00
Net Cash From Financing Activities
-1,132 -1,039 -1,216 -1,093 -110 -2,163 -1,495 -3,089 -2,967 -999 -830
Net Cash From Continuing Financing Activities
-1,132 -1,039 -1,216 -1,093 -110 -2,163 -1,495 -3,089 -2,967 -999 -830
Repayment of Debt
323 170 -4,182 631 -966 -117 -3,822 -239 -66 -1,324 1,115
Repurchase of Common Equity
-1,140 -910 -1,180 -1,367 -1,795 -1,700 -2,506 -2,505 -2,498 -2,558 -1,571
Payment of Dividends
-317 -303 -337 -357 -361 -346 -400 -345 -403 -358 -374
Issuance of Debt
2.00 4.00 4,483 - 3,012 - 5,233 - - 3,241 0.00
Other Net Changes in Cash
- - -1.00 1.00 4.00 -5.00 3.00 - -3.00 - -2.00
Cash Interest Paid
535 432 538 405 462 533 539 535 622 511 569
Cash Income Taxes Paid
297 316 1.00 998 487 358 10 136 81 1,513 -5.00

Annual Balance Sheets for HCA Healthcare

This table presents HCA Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
32,744 33,758 36,593 39,207 45,058 47,490 50,742 52,438 56,211 59,513 60,720
Total Current Assets
9,232 9,086 9,977 10,213 11,196 12,333 13,542 13,643 14,927 16,414 15,783
Cash & Equivalents
741 646 732 502 621 1,793 1,451 908 935 1,933 1,040
Accounts Receivable
5,889 5,826 6,501 6,789 7,380 7,051 8,095 8,891 9,958 10,751 10,867
Inventories, net
1,439 1,503 1,573 1,732 1,849 2,025 1,986 2,068 2,021 1,738 1,652
Other Current Assets
1,163 1,111 1,171 1,190 1,346 1,464 2,010 1,776 2,013 1,992 2,224
Plant, Property, & Equipment, net
15,014 16,352 17,895 19,757 22,715 23,199 24,063 25,575 27,715 29,414 31,141
Plant, Property & Equipment, gross
34,614 37,055 40,084 85,930 47,235 49,317 51,350 54,757 58,548 62,514 66,275
Accumulated Depreciation
19,600 20,703 22,189 23,208 24,520 26,118 27,287 29,182 30,833 33,100 35,134
Total Noncurrent Assets
8,498 8,320 8,721 9,237 11,147 11,570 13,137 13,220 13,569 13,685 13,796
Long-Term Investments
610 542 617 594 564 422 886 1,204 1,233 1,231 1,118
Goodwill
6,731 6,704 7,394 7,953 8,269 8,578 9,540 9,653 9,945 10,093 10,293
Other Noncurrent Operating Assets
1,157 1,074 710 690 2,314 2,570 2,711 2,363 2,391 2,361 2,385
Total Liabilities & Shareholders' Equity
32,744 33,758 36,593 39,207 45,058 47,490 50,742 52,438 56,211 59,513 60,720
Total Liabilities
38,790 39,391 41,588 42,125 45,623 44,598 49,253 52,511 55,151 58,958 63,491
Total Current Liabilities
5,516 5,834 6,158 7,569 7,757 8,704 9,582 9,902 12,655 15,177 16,350
Short-Term Debt
233 216 200 788 145 209 237 370 2,424 4,698 4,889
Accounts Payable
2,170 2,318 2,606 2,577 2,905 3,535 4,111 4,239 4,233 4,276 4,659
Accrued Expenses
3,113 3,300 3,352 4,204 4,707 4,960 5,234 5,293 5,998 6,203 6,802
Total Noncurrent Liabilities
33,274 33,557 35,430 34,556 37,866 35,894 39,671 42,609 42,496 43,781 47,141
Long-Term Debt
30,255 31,160 32,858 32,033 33,577 30,795 34,342 37,714 37,169 38,333 41,603
Noncurrent Deferred & Payable Income Tax Liabilities
1,904 1,249 1,374 1,248 1,420 1,940 2,060 1,615 1,867 2,041 2,219
Other Noncurrent Operating Liabilities
1,115 1,148 1,198 1,275 2,869 3,159 3,269 3,280 3,460 3,407 3,319
Total Equity & Noncontrolling Interests
-6,046 -5,633 -4,995 -2,918 -565 2,892 1,489 -73 1,060 555 -2,771
Total Preferred & Common Equity
-7,599 -7,302 -6,806 -4,950 -2,808 572 -933 -2,767 -1,774 -2,499 -6,027
Total Common Equity
-7,599 -7,302 -6,806 -4,950 -2,808 572 -933 -2,767 -1,774 -2,499 -6,027
Common Stock
4.00 4.00 4.00 3.00 3.00 297 3.00 3.00 3.00 3.00 2.00
Retained Earnings
-7,338 -6,968 -6,532 -4,572 -2,351 777 -532 -2,280 -1,352 -2,115 -5,724
Accumulated Other Comprehensive Income / (Loss)
-265 -338 -278 -381 -460 -502 -404 -490 -425 -387 -305
Noncontrolling Interest
1,553 1,669 1,811 2,032 2,243 2,320 2,422 2,694 2,834 3,054 3,256

Quarterly Balance Sheets for HCA Healthcare

This table presents HCA Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
53,594 54,589 56,211 56,962 57,379 59,459 59,513 59,798 59,536 59,747 61,450
Total Current Assets
13,888 14,294 14,927 15,282 15,173 16,662 16,414 16,258 15,563 15,285 16,052
Cash & Equivalents
862 891 935 1,284 831 2,888 1,933 1,060 939 997 940
Accounts Receivable
8,713 9,182 9,958 10,044 10,239 9,915 10,751 11,088 10,459 10,428 11,324
Inventories, net
2,050 2,030 2,021 1,903 1,800 1,776 1,738 1,794 1,792 1,734 1,681
Other Current Assets
2,263 2,191 2,013 2,051 2,303 2,083 1,992 2,316 2,373 2,126 2,107
Plant, Property, & Equipment, net
26,644 27,117 27,715 28,096 28,639 29,047 29,414 29,738 30,123 30,568 31,472
Plant, Property & Equipment, gross
56,667 57,772 58,548 59,440 60,625 61,750 62,514 63,680 64,388 65,489 67,365
Accumulated Depreciation
30,023 30,655 30,833 31,344 31,986 32,703 33,100 33,942 34,265 34,921 35,893
Total Noncurrent Assets
13,062 13,178 13,569 13,584 13,567 13,750 13,685 13,802 13,850 13,894 13,926
Long-Term Investments
1,115 1,121 1,233 1,207 1,185 1,258 1,231 1,207 1,185 1,227 1,002
Goodwill
9,641 9,778 9,945 9,967 9,963 9,982 10,093 10,237 10,273 10,275 10,504
Other Noncurrent Operating Assets
2,306 2,279 2,391 2,410 2,419 2,510 2,361 2,358 2,392 2,392 2,420
Total Liabilities & Shareholders' Equity
53,594 54,589 56,211 56,962 57,379 59,459 59,513 59,798 59,536 59,747 61,450
Total Liabilities
53,133 54,232 55,151 55,692 56,040 58,673 58,958 60,236 60,774 61,906 64,428
Total Current Liabilities
11,545 12,407 12,655 13,141 14,301 14,900 15,177 13,631 15,939 17,896 19,258
Short-Term Debt
2,395 2,553 2,424 3,028 4,574 4,682 4,698 3,519 5,104 6,110 8,532
Accounts Payable
3,823 4,139 4,233 4,735 4,029 4,235 4,276 4,488 4,250 4,552 4,806
Accrued Expenses
5,327 5,715 5,998 5,378 5,698 5,983 6,203 5,624 6,585 7,234 5,920
Total Noncurrent Liabilities
41,588 41,825 42,496 42,551 41,739 43,773 43,781 46,605 44,835 44,010 45,170
Long-Term Debt
36,537 36,793 37,169 37,163 36,306 38,283 38,333 41,057 39,379 38,401 39,491
Noncurrent Deferred & Payable Income Tax Liabilities
1,691 1,666 1,867 1,905 1,966 1,982 2,041 2,191 2,069 2,309 2,348
Other Noncurrent Operating Liabilities
3,360 3,366 3,460 3,483 3,467 3,508 3,407 3,357 3,387 3,300 3,331
Total Equity & Noncontrolling Interests
461 357 1,060 1,270 1,339 786 555 -438 -1,238 -2,159 -2,978
Total Preferred & Common Equity
-2,303 -2,477 -1,774 -1,615 -1,600 -2,182 -2,499 -3,519 -4,394 -5,335 -6,303
Total Common Equity
-2,303 -2,477 -1,774 -1,615 -1,600 -2,182 -2,499 -3,519 -4,394 -5,335 -6,303
Common Stock
3.00 3.00 3.00 3.00 3.00 3.00 3.00 2.00 2.00 2.00 2.00
Retained Earnings
-1,850 -1,989 -1,352 -1,185 -1,170 -1,807 -2,115 -3,164 -4,087 -5,020 -5,978
Accumulated Other Comprehensive Income / (Loss)
-456 -491 -425 -433 -433 -378 -387 -357 -309 -317 -327
Noncontrolling Interest
2,764 2,834 2,834 2,885 2,939 2,968 3,054 3,081 3,156 3,176 3,325

Annual Metrics And Ratios for HCA Healthcare

This table displays calculated financial ratios and metrics derived from HCA Healthcare's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
8.74% -4.82% 5.12% 7.02% 9.98% 0.38% 14.01% 2.52% 7.86% 8.67% 7.08%
EBITDA Growth
3.69% 10.68% -2.83% 14.25% 4.93% 1.46% 41.70% -5.83% -4.63% 9.40% 12.32%
EBIT Growth
3.54% 13.24% -6.22% 16.90% 2.06% 0.26% 55.73% -8.36% -7.07% 10.00% 14.13%
NOPAT Growth
6.48% 13.63% -17.70% 53.60% -1.94% 2.48% 51.35% -7.04% -7.78% 8.70% 15.66%
Net Income Growth
13.61% 27.30% -20.08% 60.01% -5.56% 5.84% 76.00% -11.49% -10.87% 9.29% 16.90%
EPS Growth
19.95% 46.29% -18.49% 79.16% -5.53% 8.54% 93.60% -9.50% -0.94% 15.97% 28.77%
Operating Cash Flow Growth
4.16% 22.02% -4.02% 24.60% 12.44% 21.44% -2.96% -4.88% 10.67% 11.48% 20.18%
Free Cash Flow Firm Growth
14.29% 17.87% -47.99% 128.26% -31.69% 156.03% -1.64% -5.51% -17.43% 26.10% 33.03%
Invested Capital Growth
6.40% 6.34% 8.79% 7.83% 10.99% -2.12% 7.79% 6.43% 7.20% 5.03% 2.82%
Revenue Q/Q Growth
2.00% -6.90% 8.22% 1.55% 2.49% 1.52% 1.33% 0.72% 2.86% 1.41% 1.65%
EBITDA Q/Q Growth
-1.15% 3.22% -0.96% 1.68% 1.84% 7.48% 1.86% 6.57% -6.41% -0.59% 4.54%
EBIT Q/Q Growth
-1.87% 3.87% -2.05% 1.78% 0.92% 11.14% 1.76% 8.37% -8.67% -1.40% 5.42%
NOPAT Q/Q Growth
2.59% 3.23% -12.08% 15.54% -0.68% 12.41% 0.48% 9.61% -9.05% -1.53% 6.15%
Net Income Q/Q Growth
2.35% 11.25% -13.93% 15.96% 0.68% 10.62% 4.20% 10.35% -11.42% -2.56% 6.53%
EPS Q/Q Growth
4.83% 15.32% -15.12% 19.11% 0.70% 10.52% 7.79% 8.75% -6.32% -1.17% 9.38%
Operating Cash Flow Q/Q Growth
-3.54% 4.47% 0.65% 6.98% 4.54% -39.74% 205.46% 1.00% 1.58% -1.08% -1.56%
Free Cash Flow Firm Q/Q Growth
15.74% -1.43% -6.38% 8.27% 10.41% -45.05% 325.61% 30.06% -13.28% -2.34% -0.76%
Invested Capital Q/Q Growth
1.47% 2.18% 0.43% 2.17% 1.05% 25.42% 4.54% 2.23% 2.11% 2.06% 3.58%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
49.47% 54.45% 83.23% 37.55% 83.48% 53.67% 54.42% 84.44% 54.61% 40.62% 41.50%
EBITDA Margin
17.55% 20.41% 18.86% 20.14% 19.21% 19.42% 24.13% 22.17% 19.60% 19.73% 20.70%
Operating Margin
13.67% 15.59% 13.91% 15.19% 14.10% 14.08% 19.23% 17.19% 14.81% 14.99% 15.98%
EBIT Margin
13.10% 15.59% 13.91% 15.19% 14.10% 14.08% 19.23% 17.19% 14.81% 14.99% 15.98%
Profit (Net Income) Margin
6.18% 8.27% 6.29% 9.40% 8.07% 8.51% 13.14% 11.35% 9.38% 9.43% 10.29%
Tax Burden Percent
68.13% 71.35% 62.61% 82.27% 79.04% 80.79% 78.52% 79.65% 79.04% 78.11% 79.15%
Interest Burden Percent
69.29% 74.38% 72.23% 75.25% 72.47% 74.84% 87.03% 82.87% 80.09% 80.53% 81.39%
Effective Tax Rate
31.87% 28.65% 37.39% 17.73% 20.96% 19.21% 21.48% 20.35% 20.96% 21.89% 20.85%
Return on Invested Capital (ROIC)
18.13% 19.37% 14.81% 21.01% 18.82% 18.53% 27.29% 23.69% 20.45% 20.95% 23.32%
ROIC Less NNEP Spread (ROIC-NNEP)
13.37% 15.38% 11.41% 16.46% 13.92% 13.69% 23.49% 19.55% 16.32% 16.79% 19.10%
Return on Net Nonoperating Assets (RNNOA)
-61.12% -78.14% -66.43% -131.94% -256.83% 358.52% 325.19% 941.57% 1,213.80% 803.44% -725.67%
Return on Equity (ROE)
-42.98% -58.77% -51.62% -110.93% -238.01% 377.05% 352.48% 965.25% 1,234.25% 824.40% -702.35%
Cash Return on Invested Capital (CROIC)
11.93% 13.22% 6.39% 13.47% 8.41% 20.68% 19.79% 17.46% 13.50% 16.04% 20.54%
Operating Return on Assets (OROA)
17.92% 19.45% 17.24% 18.71% 17.17% 15.68% 23.00% 20.07% 17.71% 18.29% 20.09%
Return on Assets (ROA)
8.46% 10.32% 7.80% 11.58% 9.84% 9.48% 15.72% 13.25% 11.21% 11.51% 12.94%
Return on Common Equity (ROCE)
-53.09% -74.99% -68.52% -164.81% -530.15% -362.31% -29.04% -2,522.20% -5,678.53% -2,181.20% -2,702.26%
Return on Equity Simple (ROE_SIMPLE)
-35.48% -47.00% -40.30% -88.67% -147.61% 766.96% -827.55% -246.98% -343.35% -266.39% 0.00%
Net Operating Profit after Tax (NOPAT)
4,061 4,614 3,797 5,833 5,720 5,861 8,871 8,247 7,605 8,267 9,561
NOPAT Margin
9.32% 11.12% 8.71% 12.50% 11.14% 11.37% 15.10% 13.69% 11.71% 11.71% 12.65%
Net Nonoperating Expense Percent (NNEP)
4.76% 3.99% 3.41% 4.55% 4.90% 4.84% 3.79% 4.14% 4.13% 4.17% 4.23%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 21.70% 18.71% 18.97% 21.87%
Cost of Revenue to Revenue
50.53% 45.55% 16.77% 62.45% 16.52% 46.33% 45.58% 15.56% 45.39% 59.38% 58.50%
SG&A Expenses to Revenue
31.41% 34.78% 64.45% 18.44% 64.36% 34.30% 33.09% 64.48% 35.06% 20.99% 21.01%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
35.79% 38.87% 69.32% 22.36% 69.38% 39.59% 35.19% 67.25% 39.80% 25.63% 25.52%
Earnings before Interest and Taxes (EBIT)
5,711 6,467 6,065 7,090 7,236 7,255 11,298 10,354 9,622 10,584 12,080
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
7,650 8,467 8,227 9,399 9,862 10,006 14,178 13,352 12,734 13,931 15,647
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 94.22 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.59 0.63 0.67 0.87 0.94 1.05 1.33 1.11 1.11 1.08 1.41
Price to Earnings (P/E)
12.17 9.02 13.19 10.76 13.78 14.36 11.22 11.82 13.71 13.20 15.70
Dividend Yield
0.00% 0.00% 0.00% 1.18% 1.12% 0.48% 0.87% 0.95% 0.89% 0.88% 0.62%
Earnings Yield
8.21% 11.08% 7.58% 9.29% 7.26% 6.97% 8.91% 8.46% 7.29% 7.58% 6.37%
Enterprise Value to Invested Capital (EV/IC)
2.45 2.36 2.35 2.59 2.60 2.72 3.34 2.94 2.91 2.94 3.71
Enterprise Value to Revenue (EV/Rev)
1.30 1.40 1.44 1.60 1.62 1.65 1.92 1.75 1.73 1.68 2.04
Enterprise Value to EBITDA (EV/EBITDA)
7.40 6.84 7.63 7.93 8.42 8.50 7.95 7.89 8.81 8.54 9.85
Enterprise Value to EBIT (EV/EBIT)
9.91 8.96 10.35 10.51 11.48 11.72 9.98 10.18 11.66 11.24 12.76
Enterprise Value to NOPAT (EV/NOPAT)
13.94 12.55 16.53 12.77 14.52 14.50 12.71 12.78 14.75 14.39 16.12
Enterprise Value to Operating Cash Flow (EV/OCF)
12.22 10.25 11.57 11.02 10.93 9.21 12.58 12.36 11.89 11.31 12.20
Enterprise Value to Free Cash Flow (EV/FCFF)
21.18 18.39 38.30 19.92 32.52 13.00 17.52 17.33 22.34 18.79 18.30
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-5.04 -5.57 -6.62 -11.25 -59.69 10.72 23.22 -521.70 37.35 77.53 -16.78
Long-Term Debt to Equity
-5.00 -5.53 -6.58 -10.98 -59.43 10.65 23.06 -516.63 35.07 69.07 -15.01
Financial Leverage
-4.57 -5.08 -5.82 -8.02 -18.45 26.19 13.84 48.17 74.36 47.86 -38.00
Leverage Ratio
-5.08 -5.69 -6.62 -9.58 -24.19 39.77 22.42 72.87 110.08 71.66 -54.26
Compound Leverage Factor
-3.52 -4.24 -4.78 -7.21 -17.53 29.77 19.51 60.38 88.16 57.70 -44.16
Debt to Total Capital
124.74% 121.88% 117.80% 109.76% 101.70% 91.47% 95.87% 100.19% 97.39% 98.73% 106.34%
Short-Term Debt to Total Capital
0.95% 0.84% 0.71% 2.64% 0.44% 0.62% 0.66% 0.97% 5.96% 10.78% 11.18%
Long-Term Debt to Total Capital
123.78% 121.04% 117.09% 107.12% 101.27% 90.85% 95.21% 99.22% 91.43% 87.95% 95.16%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
6.35% 6.48% 6.45% 6.80% 6.76% 6.84% 6.72% 7.09% 6.97% 7.01% 7.45%
Common Equity to Total Capital
-31.09% -28.37% -24.25% -16.55% -8.47% 1.69% -2.59% -7.28% -4.36% -5.73% -13.79%
Debt to EBITDA
3.99 3.71 4.02 3.49 3.42 3.10 2.44 2.85 3.11 3.09 2.97
Net Debt to EBITDA
3.81 3.57 3.85 3.38 3.30 2.88 2.27 2.69 2.94 2.86 2.83
Long-Term Debt to EBITDA
3.95 3.68 3.99 3.41 3.40 3.08 2.42 2.82 2.92 2.75 2.66
Debt to NOPAT
7.51 6.80 8.71 5.63 5.90 5.29 3.90 4.62 5.21 5.21 4.86
Net Debt to NOPAT
7.18 6.54 8.35 5.44 5.69 4.91 3.63 4.36 4.92 4.82 4.64
Long-Term Debt to NOPAT
7.45 6.75 8.65 5.49 5.87 5.25 3.87 4.57 4.89 4.64 4.35
Altman Z-Score
2.13 2.09 2.04 2.29 2.32 2.43 2.92 2.59 2.52 2.52 2.77
Noncontrolling Interest Sharing Ratio
-23.51% -27.59% -32.74% -48.57% -122.74% 196.09% 108.24% 361.30% 560.08% 364.58% -284.75%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.67 1.56 1.62 1.35 1.44 1.42 1.41 1.38 1.18 1.08 0.97
Quick Ratio
1.20 1.11 1.17 0.96 1.03 1.02 1.00 0.99 0.86 0.84 0.73
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2,673 3,150 1,638 3,740 2,555 6,540 6,433 6,079 5,019 6,330 8,420
Operating Cash Flow to CapEx
195.07% 204.82% 179.97% 189.22% 182.83% 325.64% 250.46% 193.90% 198.80% 215.67% 255.58%
Free Cash Flow to Firm to Interest Expense
1.48 1.84 0.95 2.13 1.26 3.48 4.08 3.34 2.59 3.07 3.75
Operating Cash Flow to Interest Expense
2.57 3.30 3.14 3.85 3.74 4.91 5.68 4.69 4.87 5.10 5.62
Operating Cash Flow Less CapEx to Interest Expense
1.25 1.69 1.39 1.82 1.69 3.40 3.41 2.27 2.42 2.74 3.42
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.37 1.25 1.24 1.23 1.22 1.11 1.20 1.17 1.20 1.22 1.26
Accounts Receivable Turnover
7.53 7.08 7.08 7.02 7.25 7.14 7.76 7.09 6.89 6.82 6.99
Inventory Turnover
16.21 12.85 4.76 17.64 4.74 12.33 13.35 4.62 14.42 22.31 26.09
Fixed Asset Turnover
2.97 2.65 2.55 2.48 2.42 2.24 2.49 2.43 2.44 2.47 2.50
Accounts Payable Turnover
10.48 8.42 2.97 11.25 3.09 7.41 7.00 2.24 6.96 9.85 9.90
Days Sales Outstanding (DSO)
48.49 51.53 51.58 51.96 50.37 51.11 47.05 51.47 52.95 53.53 52.19
Days Inventory Outstanding (DIO)
22.52 28.41 76.73 20.69 77.06 29.61 27.34 78.95 25.31 16.36 13.99
Days Payable Outstanding (DPO)
34.84 43.34 122.83 32.45 117.97 49.23 52.11 162.62 52.43 37.04 36.87
Cash Conversion Cycle (CCC)
36.17 36.60 5.48 40.20 9.46 31.49 22.28 -32.20 25.82 32.85 29.30
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
23,091 24,555 26,714 28,807 31,972 31,293 33,731 35,899 38,485 40,422 41,563
Invested Capital Turnover
1.95 1.74 1.70 1.68 1.69 1.63 1.81 1.73 1.75 1.79 1.84
Increase / (Decrease) in Invested Capital
1,388 1,464 2,159 2,093 3,165 -679 2,438 2,168 2,586 1,937 1,141
Enterprise Value (EV)
56,608 57,929 62,756 74,502 83,064 85,005 112,730 105,370 112,148 118,948 154,125
Market Capitalization
25,918 26,072 29,236 40,745 48,284 53,896 78,066 66,704 71,889 76,027 106,535
Book Value per Share
($18.64) ($19.49) ($19.22) ($14.38) ($8.28) $1.69 ($3.00) ($9.79) ($6.63) ($9.87) ($26.41)
Tangible Book Value per Share
($35.15) ($37.38) ($40.11) ($37.49) ($32.66) ($23.66) ($33.67) ($43.93) ($43.78) ($49.71) ($71.52)
Total Capital
24,442 25,743 28,063 29,903 33,157 33,896 36,068 38,011 40,653 43,586 43,721
Total Debt
30,488 31,376 33,058 32,821 33,722 31,004 34,579 38,084 39,593 43,031 46,492
Total Long-Term Debt
30,255 31,160 32,858 32,033 33,577 30,795 34,342 37,714 37,169 38,333 41,603
Net Debt
29,137 30,188 31,709 31,725 32,537 28,789 32,242 35,972 37,425 39,867 44,334
Capital Expenditures (CapEx)
2,375 2,760 3,015 3,573 4,158 2,835 3,577 4,395 4,744 4,875 4,944
Debt-free, Cash-free Net Working Capital (DFCFNWC)
3,208 2,822 3,287 2,930 2,963 2,045 2,746 3,203 3,761 4,002 3,282
Debt-free Net Working Capital (DFNWC)
3,949 3,468 4,019 3,432 3,584 3,838 4,197 4,111 4,696 5,935 4,322
Net Working Capital (NWC)
3,716 3,252 3,819 2,644 3,439 3,629 3,960 3,741 2,272 1,237 -567
Net Nonoperating Expense (NNE)
1,365 1,182 1,054 1,444 1,575 1,474 1,150 1,413 1,514 1,610 1,779
Net Nonoperating Obligations (NNO)
29,137 30,188 31,709 31,725 32,537 28,401 32,242 35,972 37,425 39,867 44,334
Total Depreciation and Amortization (D&A)
1,939 2,000 2,162 2,309 2,626 2,751 2,880 2,998 3,112 3,347 3,567
Debt-free, Cash-free Net Working Capital to Revenue
7.36% 6.80% 7.54% 6.28% 5.77% 3.97% 4.67% 5.32% 5.79% 5.67% 4.34%
Debt-free Net Working Capital to Revenue
9.06% 8.36% 9.21% 7.35% 6.98% 7.45% 7.14% 6.83% 7.23% 8.41% 5.72%
Net Working Capital to Revenue
8.52% 7.84% 8.76% 5.66% 6.70% 7.04% 6.74% 6.21% 3.50% 1.75% -0.75%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$5.14 $7.53 $6.12 $10.90 $10.27 $11.10 $21.52 $19.43 $19.25 $22.27 $28.70
Adjusted Weighted Average Basic Shares Outstanding
414.19M 383.59M 362.31M 347.30M 341.21M 338.27M 323.32M 290.35M 272.40M 258.60M 236.41M
Adjusted Diluted Earnings per Share
$4.99 $7.30 $5.95 $10.66 $10.07 $10.93 $21.16 $19.15 $18.97 $22.00 $28.33
Adjusted Weighted Average Diluted Shares Outstanding
426.72M 395.85M 372.22M 355.30M 348.23M 343.61M 328.75M 294.67M 276.41M 261.81M 239.50M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $10.27 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
396.96M 370.15M 349.90M 342.38M 338.43M 339.92M 303.60M 276.97M 264.50M 248.34M 223.62M
Normalized Net Operating Profit after Tax (NOPAT)
4,064 4,598 3,792 5,481 5,705 5,867 7,599 7,211 7,609 8,256 9,532
Normalized NOPAT Margin
9.32% 11.08% 8.70% 11.74% 11.11% 11.39% 12.93% 11.97% 11.71% 11.69% 12.61%
Pre Tax Income Margin
9.08% 11.59% 10.04% 11.43% 10.22% 10.54% 16.74% 14.24% 11.86% 12.07% 13.01%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
3.17 3.78 3.51 4.04 3.56 3.86 7.16 5.69 4.96 5.14 5.37
NOPAT to Interest Expense
2.26 2.70 2.20 3.32 2.81 3.12 5.62 4.53 3.92 4.01 4.25
EBIT Less CapEx to Interest Expense
1.85 2.17 1.76 2.00 1.51 2.35 4.89 3.28 2.52 2.77 3.17
NOPAT Less CapEx to Interest Expense
0.94 1.08 0.45 1.29 0.77 1.61 3.36 2.12 1.48 1.65 2.05
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
18.36% 12.65% 16.33% 21.14% 26.35% 17.76% 17.78% 24.55% 21.36% 21.05% 19.35%
Augmented Payout Ratio
107.27% 92.80% 91.10% 56.00% 51.22% 27.81% 124.18% 126.98% 83.93% 111.81% 148.72%

Quarterly Metrics And Ratios for HCA Healthcare

This table displays calculated financial ratios and metrics derived from HCA Healthcare's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - - 223,622,200.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 223,622,200.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 7.24
Growth Metrics
- - - - - - - - - - -
Revenue Growth
8.30% 11.65% 11.21% 10.28% 7.86% 5.68% 5.66% 6.36% 9.57% 6.72% 4.30%
EBITDA Growth
-0.83% -19.40% 12.54% 16.21% 13.41% -2.29% 4.60% 7.59% 18.48% 19.18% 2.04%
EBIT Growth
-2.15% -24.42% 14.91% 19.21% 14.90% -5.31% 3.52% 8.06% 23.15% 23.21% 0.21%
NOPAT Growth
-2.96% -25.15% 14.79% 15.18% 14.21% -5.69% 1.23% 12.20% 24.65% 26.18% 3.75%
Net Income Growth
-5.13% -29.67% 16.79% 19.48% 16.24% -9.40% 1.28% 12.09% 28.41% 28.29% 1.75%
EPS Growth
0.00% -17.78% 22.27% 28.90% 24.81% -4.39% 8.77% 23.51% 42.62% 42.93% 10.85%
Operating Cash Flow Growth
-17.91% 5.82% 36.94% -20.36% 41.79% -4.30% -33.13% 113.60% 25.63% -7.82% 21.99%
Free Cash Flow Firm Growth
19.45% -141.45% 223.83% -253.17% 95.38% 151.91% -311.49% 295.28% 4,284.64% 757.40% 265.16%
Invested Capital Growth
7.33% 7.20% 5.13% 7.45% 5.08% 5.03% 7.44% 2.28% 1.32% 2.82% 2.94%
Revenue Q/Q Growth
2.22% 6.72% 0.21% 0.88% -0.03% 4.56% 0.20% 1.55% 2.99% 1.84% -2.07%
EBITDA Q/Q Growth
-6.51% 26.18% -1.68% 0.20% -8.77% 8.72% 5.25% 3.06% 0.47% 9.35% -9.88%
EBIT Q/Q Growth
-9.00% 34.96% -2.37% -0.58% -12.29% 11.22% 6.73% 3.78% -0.03% 11.27% -13.19%
NOPAT Q/Q Growth
-8.80% 36.92% -1.34% -6.51% -9.56% 13.07% 5.89% 3.62% 0.48% 14.45% -12.93%
Net Income Q/Q Growth
-9.70% 45.96% -3.17% -6.38% -12.15% 13.77% 8.24% 3.62% 0.63% 13.66% -14.15%
EPS Q/Q Growth
-8.86% 51.41% 0.17% -6.75% -11.75% 15.98% 13.96% 5.89% 1.90% 16.24% -11.62%
Operating Cash Flow Q/Q Growth
0.16% 7.87% -7.67% -20.17% 78.34% -27.20% -35.48% 155.00% 4.89% -46.58% -14.62%
Free Cash Flow Firm Q/Q Growth
-299.57% 63.33% 191.06% -329.82% 93.98% 512.25% -470.99% 312.20% 28.94% -15.53% -28.54%
Invested Capital Q/Q Growth
0.74% 2.11% 1.26% 3.16% -1.49% 2.06% 3.58% -1.79% -2.41% 3.58% 3.71%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
53.40% 28.52% 40.15% 84.94% 55.05% -15.13% 56.35% 56.26% 56.35% -1.10% 56.65%
EBITDA Margin
17.71% 20.94% 20.55% 20.41% 18.63% 19.37% 20.34% 20.65% 20.14% 21.63% 19.90%
Operating Margin
12.92% 16.33% 15.91% 15.68% 13.76% 14.63% 15.59% 15.93% 15.46% 16.90% 14.98%
EBIT Margin
12.92% 16.33% 15.91% 15.68% 13.76% 14.63% 15.59% 15.93% 15.46% 16.90% 14.98%
Profit (Net Income) Margin
7.86% 10.76% 10.39% 9.64% 8.47% 9.22% 9.96% 10.16% 9.93% 11.08% 9.72%
Tax Burden Percent
78.22% 79.36% 80.20% 75.41% 77.75% 79.04% 78.43% 78.30% 78.70% 80.95% 81.20%
Interest Burden Percent
77.84% 82.98% 81.44% 81.55% 79.22% 79.71% 81.48% 81.48% 81.61% 81.04% 79.91%
Effective Tax Rate
21.78% 20.64% 19.80% 24.59% 22.25% 20.96% 21.57% 21.70% 21.30% 19.05% 18.80%
Return on Invested Capital (ROIC)
17.53% 22.64% 22.39% 20.83% 19.27% 20.70% 21.65% 22.30% 22.70% 25.23% 21.86%
ROIC Less NNEP Spread (ROIC-NNEP)
16.54% 21.60% 21.29% 19.82% 18.25% 19.59% 20.61% 21.24% 21.65% 24.02% 20.81%
Return on Net Nonoperating Assets (RNNOA)
-2,876.48% 1,606.35% 1,056.56% 834.85% 1,215.96% 937.58% 1,982.42% 17,084.29% -1,278.68% -912.81% -538.42%
Return on Equity (ROE)
-2,858.95% 1,628.99% 1,078.95% 855.68% 1,235.23% 958.28% 2,004.07% 17,106.59% -1,255.97% -887.59% -516.56%
Cash Return on Invested Capital (CROIC)
15.90% 13.50% 15.76% 13.85% 16.77% 16.04% 13.34% 18.76% 21.28% 20.54% 19.80%
Operating Return on Assets (OROA)
15.38% 19.53% 19.36% 19.32% 16.80% 17.86% 19.11% 19.81% 19.30% 21.25% 18.87%
Return on Assets (ROA)
9.37% 12.86% 12.64% 11.88% 10.35% 11.25% 12.21% 12.64% 12.39% 13.94% 12.24%
Return on Common Equity (ROCE)
-39,706.19% -7,494.69% -2,952.39% -1,855.39% -5,034.94% -2,535.45% -12,366.45% -1,015,216.81% -6,876.30% -3,414.96% -1,485.26%
Return on Equity Simple (ROE_SIMPLE)
-277.59% 0.00% -393.19% -414.06% -313.11% 0.00% -189.83% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1,638 2,243 2,213 2,069 1,871 2,115 2,240 2,321 2,332 2,669 2,324
NOPAT Margin
10.10% 12.96% 12.76% 11.83% 10.70% 11.57% 12.23% 12.47% 12.17% 13.68% 12.16%
Net Nonoperating Expense Percent (NNEP)
0.99% 1.04% 1.10% 1.01% 1.02% 1.11% 1.04% 1.06% 1.06% 1.20% 1.06%
Return On Investment Capital (ROIC_SIMPLE)
- 5.52% - - - 4.85% 5.07% 5.37% 5.51% 6.10% 5.16%
Cost of Revenue to Revenue
46.60% 71.48% 59.85% 15.06% 44.95% 115.13% 43.65% 43.74% 43.65% 101.10% 43.35%
SG&A Expenses to Revenue
35.75% 7.77% 20.80% 64.65% 36.45% -35.38% 36.07% 35.67% 36.24% -22.05% 36.80%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
40.48% 12.18% 24.23% 69.26% 41.29% -29.77% 40.76% 40.33% 40.89% -17.99% 41.68%
Earnings before Interest and Taxes (EBIT)
2,094 2,826 2,759 2,743 2,406 2,676 2,856 2,964 2,963 3,297 2,862
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,872 3,624 3,563 3,570 3,257 3,541 3,727 3,841 3,859 4,220 3,803
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.05 1.11 1.34 1.23 1.51 1.08 1.20 1.27 1.34 1.41 1.39
Price to Earnings (P/E)
11.61 13.71 16.29 14.67 17.69 13.20 14.85 15.44 15.72 15.70 15.58
Dividend Yield
0.97% 0.89% 0.74% 0.78% 0.63% 0.88% 0.78% 0.72% 0.66% 0.62% 0.62%
Earnings Yield
8.61% 7.29% 6.14% 6.82% 5.65% 7.58% 6.73% 6.48% 6.36% 6.37% 6.42%
Enterprise Value to Invested Capital (EV/IC)
2.83 2.91 3.33 3.13 3.70 2.94 3.13 3.35 3.62 3.71 3.60
Enterprise Value to Revenue (EV/Rev)
1.69 1.73 1.94 1.84 2.11 1.68 1.83 1.89 1.95 2.04 2.03
Enterprise Value to EBITDA (EV/EBITDA)
7.83 8.81 9.88 9.24 10.47 8.54 9.31 9.58 9.70 9.85 9.87
Enterprise Value to EBIT (EV/EBIT)
10.11 11.66 12.99 12.09 13.66 11.24 12.28 12.63 12.67 12.76 12.84
Enterprise Value to NOPAT (EV/NOPAT)
12.74 14.75 16.43 15.43 17.47 14.39 15.82 16.11 16.12 16.12 16.10
Enterprise Value to Operating Cash Flow (EV/OCF)
11.48 11.89 12.84 13.13 13.80 11.31 13.53 11.54 11.31 12.20 11.94
Enterprise Value to Free Cash Flow (EV/FCFF)
18.41 22.34 21.65 23.43 22.63 18.79 24.33 18.05 17.11 18.30 18.45
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
110.21 37.35 31.65 30.53 54.66 77.53 -101.77 -35.93 -20.62 -16.78 -16.13
Long-Term Debt to Equity
103.06 35.07 29.26 27.11 48.71 69.07 -93.74 -31.81 -17.79 -15.01 -13.26
Financial Leverage
-173.94 74.36 49.63 42.12 66.63 47.86 96.16 804.19 -59.07 -38.00 -25.88
Leverage Ratio
-251.95 110.08 73.02 61.65 99.78 71.66 140.34 1,157.57 -86.82 -54.26 -35.49
Compound Leverage Factor
-196.13 91.34 59.47 50.28 79.04 57.12 114.34 943.17 -70.85 -43.97 -28.36
Debt to Total Capital
99.10% 97.39% 96.94% 96.83% 98.20% 98.73% 100.99% 102.86% 105.10% 106.34% 106.61%
Short-Term Debt to Total Capital
6.43% 5.96% 7.30% 10.83% 10.70% 10.78% 7.97% 11.80% 14.43% 11.18% 18.94%
Long-Term Debt to Total Capital
92.67% 91.43% 89.63% 85.99% 87.50% 87.95% 93.02% 91.06% 90.67% 95.16% 87.67%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
7.14% 6.97% 6.96% 6.96% 6.78% 7.01% 6.98% 7.30% 7.50% 7.45% 7.38%
Common Equity to Total Capital
-6.24% -4.36% -3.90% -3.79% -4.99% -5.73% -7.97% -10.16% -12.60% -13.79% -13.99%
Debt to EBITDA
2.89 3.11 3.06 3.00 3.07 3.09 3.16 3.10 2.97 2.97 3.05
Net Debt to EBITDA
2.74 2.94 2.87 2.85 2.77 2.86 3.00 2.95 2.83 2.83 2.93
Long-Term Debt to EBITDA
2.70 2.92 2.83 2.66 2.73 2.75 2.91 2.74 2.57 2.66 2.51
Debt to NOPAT
4.71 5.21 5.09 5.01 5.12 5.21 5.37 5.20 4.94 4.86 4.98
Net Debt to NOPAT
4.46 4.92 4.78 4.76 4.62 4.82 5.10 4.96 4.69 4.64 4.78
Long-Term Debt to NOPAT
4.40 4.89 4.71 4.45 4.56 4.64 4.95 4.61 4.26 4.35 4.09
Altman Z-Score
2.01 2.12 2.31 2.24 2.37 2.08 2.19 2.19 2.20 2.29 2.18
Noncontrolling Interest Sharing Ratio
-1,288.84% 560.08% 373.64% 316.83% 507.61% 364.58% 717.07% 6,034.65% -447.49% -284.75% -187.53%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.15 1.18 1.16 1.06 1.12 1.08 1.19 0.98 0.85 0.97 0.83
Quick Ratio
0.81 0.86 0.86 0.77 0.86 0.84 0.89 0.72 0.64 0.73 0.64
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-936 -343 313 -718 -43 178 -661 1,403 1,809 1,528 1,092
Operating Cash Flow to CapEx
216.13% 230.72% 220.84% 153.86% 295.13% 199.14% 166.60% 357.99% 342.86% 158.43% 179.98%
Free Cash Flow to Firm to Interest Expense
-1.94 -0.70 0.61 -1.42 -0.08 0.34 -1.21 2.47 3.22 2.67 1.87
Operating Cash Flow to Interest Expense
5.13 5.45 4.82 3.90 6.83 4.85 3.02 7.41 7.87 4.12 3.45
Operating Cash Flow Less CapEx to Interest Expense
2.76 3.09 2.64 1.36 4.51 2.41 1.21 5.34 5.58 1.52 1.53
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.19 1.20 1.22 1.23 1.22 1.22 1.23 1.24 1.25 1.26 1.26
Accounts Receivable Turnover
7.12 6.89 7.14 7.21 7.29 6.82 6.78 7.02 7.31 6.99 6.82
Inventory Turnover
11.97 14.42 16.44 17.11 17.47 22.31 21.39 25.08 25.96 26.09 25.62
Fixed Asset Turnover
2.42 2.44 2.46 2.47 2.48 2.47 2.48 2.47 2.50 2.50 2.50
Accounts Payable Turnover
5.82 6.96 7.71 8.39 7.94 9.85 8.58 10.88 10.37 9.90 9.58
Days Sales Outstanding (DSO)
51.24 52.95 51.16 50.61 50.06 53.53 53.87 51.96 49.92 52.19 53.54
Days Inventory Outstanding (DIO)
30.49 25.31 22.20 21.33 20.90 16.36 17.06 14.55 14.06 13.99 14.25
Days Payable Outstanding (DPO)
62.66 52.43 47.34 43.51 45.97 37.04 42.57 33.54 35.21 36.87 38.11
Cash Conversion Cycle (CCC)
19.07 25.82 26.01 28.43 24.98 32.85 28.37 32.97 28.78 29.30 29.69
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
37,691 38,485 38,970 40,203 39,605 40,422 41,871 41,121 40,128 41,563 43,103
Invested Capital Turnover
1.74 1.75 1.75 1.76 1.80 1.79 1.77 1.79 1.87 1.84 1.80
Increase / (Decrease) in Invested Capital
2,574 2,586 1,900 2,787 1,914 1,937 2,901 918 523 1,141 1,232
Enterprise Value (EV)
106,542 112,148 129,685 125,951 146,676 118,948 131,205 137,679 145,191 154,125 155,233
Market Capitalization
66,374 71,889 89,100 84,148 104,889 76,027 85,815 92,164 99,728 106,535 105,827
Book Value per Share
($9.11) ($6.63) ($6.11) ($6.11) ($8.46) ($9.87) ($14.17) ($18.26) ($22.80) ($26.41) ($28.19)
Tangible Book Value per Share
($45.06) ($43.78) ($43.80) ($44.15) ($47.13) ($49.71) ($55.39) ($60.97) ($66.71) ($71.52) ($75.16)
Total Capital
39,703 40,653 41,461 42,219 43,751 43,586 44,138 43,245 42,352 43,721 45,045
Total Debt
39,346 39,593 40,191 40,880 42,965 43,031 44,576 44,483 44,511 46,492 48,023
Total Long-Term Debt
36,793 37,169 37,163 36,306 38,283 38,333 41,057 39,379 38,401 41,603 39,491
Net Debt
37,334 37,425 37,700 38,864 38,819 39,867 42,309 42,359 42,287 44,334 46,081
Capital Expenditures (CapEx)
1,147 1,159 1,118 1,281 1,191 1,285 991 1,176 1,288 1,489 1,119
Debt-free, Cash-free Net Working Capital (DFCFNWC)
3,549 3,761 3,885 4,615 3,556 4,002 5,086 3,789 2,502 3,282 4,386
Debt-free Net Working Capital (DFNWC)
4,440 4,696 5,169 5,446 6,444 5,935 6,146 4,728 3,499 4,322 5,326
Net Working Capital (NWC)
1,887 2,272 2,141 872 1,762 1,237 2,627 -376 -2,611 -567 -3,206
Net Nonoperating Expense (NNE)
363 382 411 382 389 429 415 430 429 506 467
Net Nonoperating Obligations (NNO)
37,334 37,425 37,700 38,864 38,819 39,867 42,309 42,359 42,287 44,334 46,081
Total Depreciation and Amortization (D&A)
778 798 804 827 851 865 871 877 896 923 941
Debt-free, Cash-free Net Working Capital to Revenue
5.62% 5.79% 5.82% 6.75% 5.11% 5.67% 7.10% 5.21% 3.36% 4.34% 5.74%
Debt-free Net Working Capital to Revenue
7.03% 7.23% 7.75% 7.97% 9.26% 8.41% 8.59% 6.50% 4.70% 5.72% 6.97%
Net Working Capital to Revenue
2.99% 3.50% 3.21% 1.28% 2.53% 1.75% 3.67% -0.52% -3.51% -0.75% -4.20%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$3.98 $6.00 $6.01 $5.60 $4.94 $5.72 $6.52 $6.91 $7.05 $8.22 $7.25
Adjusted Weighted Average Basic Shares Outstanding
271.17M 272.40M 264.44M 261.16M 256.76M 258.60M 246.94M 239.17M 232.89M 236.41M 223.59M
Adjusted Diluted Earnings per Share
$3.91 $5.92 $5.93 $5.53 $4.88 $5.66 $6.45 $6.83 $6.96 $8.09 $7.15
Adjusted Weighted Average Diluted Shares Outstanding
275.42M 276.41M 268.02M 264.07M 259.92M 261.81M 249.44M 241.91M 236.18M 239.50M 226.65M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
267.66M 264.50M 261.91M 258.07M 253.30M 248.34M 240.57M 233.99M 228.19M 223.62M 221.84M
Normalized Net Operating Profit after Tax (NOPAT)
1,636 2,237 2,051 2,060 1,874 2,269 2,239 2,323 2,333 2,636 2,325
Normalized NOPAT Margin
10.09% 12.93% 11.83% 11.77% 10.72% 12.41% 12.22% 12.49% 12.18% 13.51% 12.17%
Pre Tax Income Margin
10.05% 13.55% 12.96% 12.79% 10.90% 11.67% 12.70% 12.98% 12.62% 13.69% 11.97%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
4.34 5.76 5.39 5.42 4.67 5.07 5.22 5.22 5.28 5.76 4.90
NOPAT to Interest Expense
3.39 4.57 4.32 4.09 3.63 4.01 4.09 4.09 4.16 4.67 3.98
EBIT Less CapEx to Interest Expense
1.96 3.40 3.21 2.89 2.36 2.63 3.41 3.15 2.99 3.16 2.98
NOPAT Less CapEx to Interest Expense
1.02 2.21 2.14 1.56 1.32 1.57 2.28 2.02 1.86 2.06 2.06
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
23.69% 21.36% 20.09% 19.83% 19.88% 21.05% 21.92% 21.09% 20.45% 19.35% 18.94%
Augmented Payout Ratio
87.97% 83.93% 85.37% 89.22% 96.75% 111.81% 132.22% 144.65% 146.52% 148.72% 135.81%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, data-driven look at HCA Healthcare (NYSE: HCA) using the last four years of quarterly statements. The focus is on trends in revenue, cash flow, profitability, leverage, and capital spending that may matter to retail investors.

  • Top-line growth: Operating Revenue rose from about $15.5B in Q4 2022 to about $19.5B in Q4 2025, reflecting a multi-year positive trend in revenue.
  • Healthy operating cash flow: Net cash from continuing operating activities has generally run in the $2.0B–$2.6B range per quarter, with Q4 2025 at $2.359B and Q4 2024 at $2.556B, indicating solid cash generation from core operations.
  • Solid earnings visibility: Net income attributable to common shareholders has been substantial in recent years (Q4 2025 around $1.878B; Q4 2024 around $1.438B; Q4 2023 around $1.071B), suggesting meaningful profitability despite quarterly volatility.
  • Dividend stability: The company has consistently paid a per-share dividend in the range of roughly $0.66–$0.72 over recent quarters (for example, Q4 2025 shows $0.72 per share; Q1 2025 shows $0.66 per share). This can be attractive for income-focused investors.
  • Leverage appears high but persistent: Long-term debt has hovered in the high-40s to high-30s billions range in recent periods (roughly $38.3B–$39.4B), indicating a large but relatively stable debt load that readers should monitor relative to cash flow.
  • Capex ongoing: Purchases of property, plant & equipment (capex) run around $1.0B–$1.5B per quarter, signaling continued investment in facilities and equipment to support operations and potential growth.
  • Quarterly margin pressure: In Q4 2025, gross profit was negative (Operating Revenue $19.513B vs. Operating Cost of Revenue $19.727B, a gross loss of about $214M), highlighting near-term margin stress that needs to be watched.
  • Financing activity outflows: Net cash from financing activities has often been negative in recent quarters, reflecting actions like debt issuance/repayment, share repurchases, and dividends (for example, Q4 2025 shows a notable financing outflow). This reduces cash balance despite strong operating cash flow.
  • Equity metrics show restatements: In a number of periods, Total Common Equity and related equity figures show negative values due to accounting adjustments/restatements (e.g., Q3 2025 Total Common Equity around -$5.34B), which can complicate the fundamental picture for some investors.

Bottom-line perspective for investors: HCA has demonstrated resilient revenue growth and solid operating cash flow over the last four years, along with meaningful net income and a steady dividend. However, margin volatility, a very large debt load, financing outflows, and occasional equity restatements are important considerations. If you’re weighing this stock, you may want to focus on whether the company can stabilize gross margins and continue generating consistent free cash flow relative to its leverage over the next few quarters.

05/14/26 06:18 AM ETAI Generated. May Contain Errors.

HCA Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, HCA Healthcare's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

HCA Healthcare's net income appears to be on an upward trend, with a most recent value of $7.78 billion in 2025, rising from $2.70 billion in 2015. The previous period was $6.66 billion in 2024. Check out HCA Healthcare's forecast to explore projected trends and price targets.

HCA Healthcare's total operating income in 2025 was $12.08 billion, based on the following breakdown:
  • Total Gross Profit: $31.37 billion
  • Total Operating Expenses: $19.29 billion

Over the last 10 years, HCA Healthcare's total revenue changed from $43.59 billion in 2015 to $75.60 billion in 2025, a change of 73.4%.

HCA Healthcare's total liabilities were at $63.49 billion at the end of 2025, a 7.7% increase from 2024, and a 63.7% increase since 2015.

In the past 10 years, HCA Healthcare's cash and equivalents has ranged from $502 million in 2018 to $1.93 billion in 2024, and is currently $1.04 billion as of their latest financial filing in 2025.

Over the last 10 years, HCA Healthcare's book value per share changed from -18.64 in 2015 to -26.41 in 2025, a change of 41.7%.



Financial statements for NYSE:HCA last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners